{"filings":[{"id":1194757,"accession_number":"0001193125-26-277504","cik":2091349,"company_name":"First Tracks Biotherapeutics, Inc.","ticker":"TRAX","form_type":"8-K","filed_at":"2026-06-22T20:05:16+00:00","items":["1.01"],"status":"ready","headline":"First Tracks Biotherapeutics subleases 45,057 sq ft San Diego office from AnaptysBio for 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Subleased 45,057 rentable square feet at 10770 Wateridge Circle, San Diego from AnaptysBio, Inc.","Term began June 15, 2026 for 12 months; renewal option to April 2028 or +12 months with 3-month notice.","Monthly rent equals AnaptysBio's base rent plus additional rent under master lease, paid in advance.","Company can terminate sublease at any time with at least 3 months' prior written notice.","Sublease is subordinate to master lease; AnaptysBio remains liable to master landlord."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":581310000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":443279,"accession_number":"0001193125-26-224124","cik":2091349,"company_name":"First Tracks Biotherapeutics, Inc.","ticker":"TRAX","form_type":"8-K","filed_at":"2026-05-14T20:24:52+00:00","items":["2.02","9.01"],"status":"ready","headline":"First Tracks Q1 net loss $50.5M; launched with $180M cash; ANB033 Phase 1b data expected Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $50.5M for Q1 2026 vs $47.2M in Q1 2025; R&D expense $34.0M (down from $41.5M).","Launched on April 20 with $180M cash and a two-year runway to fund ANB033 and other programs.","ANB033 Phase 1b trials in celiac disease and eosinophilic esophagitis ongoing; top-line data Q4 2026 and mid-2027.","Rosnilimab had productive End-of-Phase 2 FDA meeting for RA; company assessing strategic options.","G&A expense rose to $18.9M from $9.8M due to separation costs and stock compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":581310000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97662,"accession_number":"0001193125-26-164328","cik":2091349,"company_name":"First Tracks Biotherapeutics, Inc.","ticker":"TRAX","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["1.01","2.01","3.02","3.03","5.03","5.01","5.02","8.01","9.01"],"status":"ready","headline":"First Tracks Biotherapeutics completes spin-off from AnaptysBio and raises ~$80M in private placement","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Spin-off effective April 20, 2026; AnaptysBio holders received one First Tracks share per AnaptysBio share held on April 6 record date.","Private placement of ~10.5M shares at $13.81: company issued 5.79M shares (~$80M proceeds) and selling stockholder sold 4.71M shares.","Entered Separation and Distribution and Transition Services Agreements with AnaptysBio to govern asset/liability split and post-spin operations.","First Tracks received $100M cash and rights to up to $35M in milestone payments from Vanda Pharmaceuticals collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":581310000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97661,"accession_number":"0001193125-26-140835","cik":2091349,"company_name":"First Tracks Biotherapeutics, Inc.","ticker":"TRAX","form_type":"8-K","filed_at":"2026-04-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"First Tracks Biotherapeutics spin-off from AnaptysBio effective April 20; $80M PIPE at $13.81/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Spin-off of biopharma assets: holders receive 1 share TRAX per ANAB share held on April 6 record date.","First Tracks starts with ~$180M cash and two-year runway; pipeline includes ANB033, rosnilimab, ANB101.","Concurrent $80M private placement: 5.79M shares at $13.81/sh to close after spin-off; Leerink & Barclays as placement agents.","Expected when-issued trading under TRAXV from April 6; regular-way TRAX trading starts April 20 on Nasdaq.","Spin-off expected to be a taxable transaction for U.S. federal income tax purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":581310000.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}